Sign up to save your podcasts
Or
Share Navigating Between Endocrine Therapy, Chemotherapy, and CDK 4/6 Inhibitors for High-Risk HR+/HER2- Early Breast Cancer: The Great Debate
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Navigating Between Endocrine Therapy, Chemotherapy, and CDK 4/6 Inhibitors for High-Risk HR+/HER2- Early Breast Cancer: The Great Debate
What strategies are you using to individualize treatment of HR+/HER2- early breast cancer?
Credit available for this activity expires: 11/17/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/998210?ecd=bdc_podcast_libsyn_mscpedu
View all episodes
By Medscape
4.3
2323 ratings
What strategies are you using to individualize treatment of HR+/HER2- early breast cancer?
Credit available for this activity expires: 11/17/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/998210?ecd=bdc_podcast_libsyn_mscpedu
More shows like Keeping Current CME
View all
The Bob Harrington Show
13 Listeners
NEJM This Week
315 Listeners
Diabetes Core Update
107 Listeners
JACC This Week
172 Listeners
This Week in Cardiology
865 Listeners
JAMA Clinical Reviews
496 Listeners
AFP: American Family Physician Podcast
689 Listeners
One-on-One with Eric Topol
18 Listeners
Mayo Clinic Talks
278 Listeners
Frankly Speaking About Family Medicine
254 Listeners
The Curbsiders Internal Medicine Podcast
3,321 Listeners
Eagle's Eye View: Your Weekly CV Update From ACC.org
137 Listeners
Core IM | Internal Medicine Podcast
1,109 Listeners
The Peter Attia Drive
7,996 Listeners
Annals On Call Podcast
194 Listeners
Medicine and the Machine
60 Listeners
Keeping Current
8 Listeners
Cardionerds: A Cardiology Podcast
424 Listeners
The Cribsiders
314 Listeners